Triclabendazole efficacy, prevalence, and re-infection of Fasciola hepatica in bovine and ovine naturally infected in the Andes of Ecuador.

Autor: Rodríguez-Hidalgo R; Research Institute of Zoonoses (CIZ), Universidad Central del Ecuador, Quito, Ecuador; Facultad de Medicina Veterinaria y Zootecnia, Universidad Central del Ecuador, Quito, Ecuador. Electronic address: rrodriguez@uce.edu.ec., Calvopiña M; One Health Research Group, Facultad de Medicina, Universidad de las Américas (UDLA), Quito, Ecuador., Romero-Alvarez D; Biodiversity Institute and Department of Ecology & Evolutionary Biology, University of Kansas, Lawrence, KS, USA., Montenegro-Franco M; Facultad de Medicina Veterinaria y Zootecnia, Universidad Central del Ecuador, Quito, Ecuador., Pavon D; Facultad de Medicina Veterinaria y Zootecnia, Universidad Central del Ecuador, Quito, Ecuador., Pointier JP; PSL Research University, USR 3278 CNRS-EPHE, CRIOBE Université de Perpignan, Perpignan-Francia, France., Benítez-Ortiz W; Research Institute of Zoonoses (CIZ), Universidad Central del Ecuador, Quito, Ecuador; Facultad de Medicina Veterinaria y Zootecnia, Universidad Central del Ecuador, Quito, Ecuador., Celi-Erazo M; Research Institute of Zoonoses (CIZ), Universidad Central del Ecuador, Quito, Ecuador.
Jazyk: angličtina
Zdroj: Veterinary parasitology, regional studies and reports [Vet Parasitol Reg Stud Reports] 2024 Jan; Vol. 47, pp. 100947. Date of Electronic Publication: 2023 Nov 05.
DOI: 10.1016/j.vprsr.2023.100947
Abstrakt: Fasciola spp., infections are distributed worldwide including the Andes region of Ecuador, affecting cattle, sheep, porcine, humans, and other herbivores. Triclabendazole (TCBZ) is commonly used to treat animal infections. However, prospective studies on TCBZ efficacy and fascioliosis prevalence have not been studied in the highlands of Ecuador. This study was performed in a rural community at central of the Ecuadorian Andes in freely roaming bovine and ovine aimed to 1) evaluate the efficacy of TCBZ by administering a single oral dose of 12 mg/kg body weight, 2) assess the prevalence of F. hepatica infection and 3) to monitor re-infections for a follow-up period of five months. In total, 122, 86, 111, 110, 89, and 90 and 49, 34, 47, 28, 27, and 31 stool samples were collected each month from bovines and ovine, respectively. Besides, 32 stool samples from porcine were also collected at the beginning of the study. Stools were microscopically analyzed by formalin-ether concentration method to detect F. hepatica ova. The prevalence of F. hepatica infections before treatment was 55,7% and 63,3% for bovine and ovine, respectively. The infection prevalence was of 22% in porcine. The efficacity of triclabendazole was 83% and 97% in bovines and ovine, respectively, at 30 days post-treatment. The re-infection reaches to 54,4% in bovines and 61,3% in ovine after five months. TCBZ had a high efficacy and could be used for bovines and ovine Fasciola infections in the study region; however, re-infections reach the initial prevalence after five months. Therefore, we recommend integrated control strategies, including chemotherapy with a single oral dose of TCBZ, vector control, and future drug resistance studies.
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: